Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms [Phase 1, Phase 2]
A Phase 1/2 clinical trial investigating focused ultrasound targeting the default mode network to reduce depressive symptoms.
-
FDA approval · 2024-03-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Camber Pharmaceuticals, approving a new supplement to an existing…
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure [Phase 4]
Phase 4 clinical trial update on personalized treatments for depressive symptoms in patients with advanced heart failure has completed with …
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Theta Burst Stimulation in Young Adults With Depression [NA]
Clinical trial update reporting completion and results for theta burst stimulation in young adults with depression.
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Collaborative Care for Women Veterans [NA]
A completed clinical trial update on collaborative care for women veterans addressing anxiety and depression; results posted in 2024.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-03-15FDA Approved: ARIPIPRAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for aripiprazole submitted by Chartwell RX, LLC, indicating regulatory approval of a supplement rela…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Improving Outcomes for Older Veterans With Chronic Back Pain and Depression [NA]
A completed clinical trial investigating outcomes for older veterans with chronic back pain and depression; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression [Phase 4]
A Phase 4 clinical trial evaluating the effectiveness of ketamine treatment administered over three consecutive days in patients with depres…
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: Effects of Open-label Placebos on COVID-related Psychological Health [NA]
Completed clinical trial investigating effects of open-label placebos on COVID-related psychological health (stress, anxiety, depression).
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial [Phase 4]
A Phase 4 randomized trial comparing tizanidine to zolpidem for primary insomnia evaluating efficacy in adults with depressive disorders; cu…
-
FDA approval · 2024-03-11FDA Approved: QUETIAPINE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for a generic version of quetiapine, enabling Solco Healthcare U.S., LLC to market a generic quetiap…
-
FDA approval · 2024-03-08FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for escitalopram oxalate (escitalopram) by Sun Pharmaceutical Industries, enabling marketing of the …
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine [Phase 1]
Phase 1 trial investigating [11C]-(R)-Rolipram to measure cAMP signaling before and after ketamine in depression; study terminated.
-
FDA approval · 2024-02-29FDA Tentative Approval: TRAZODONE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA issued tentative approval for a generic trazodone hydrochloride product from Zydus Lifesciences Limited under ANDA205253. This is a tent…
-
CLINICAL_TRIALS trial_result · 2024-02-29Clinical Trial Update: A Study of MD-120 in Patients With Depression [Phase 3]
Phase 3 trial update for MD-120 in major depressive disorder has completed with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-02-21Clinical Trial Update: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression [Phase 4]
A Phase 4 trial investigating the effects of rTMS and SSRI antidepressants on leukocyte expression of C-FOS and DUSP1 in patients with depre…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression [Phase 3]
A Phase 3 long-term safety study of esketamine nasal spray for treatment-resistant depression has completed, with results posted in 2024. Th…
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: Stellate Ganglion Block for Major Depressive Disorder. [Phase 4]
Phase 4 clinical trial update on stellate ganglion block as treatment for treatment-resistant depression and major depressive disorder has c…
-
CLINICAL_TRIALS trial_result · 2024-02-09Clinical Trial Update: Predictors of Intravenous Ketamine Response in TRD [Phase 3]
A Phase 3 trial update investigating predictors of intravenous ketamine response in treatment-resistant depression and major depressive diso…
-
CLINICAL_TRIALS research · 2024-02-08Clinical Trial Update: Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer [NA]
A completed clinical trial evaluating proactive psychiatry consultation and case management for patients with cancer and severe major depres…
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Augmenting Hospitalization for Serious Mental Illness: Cognitive Bias Modification [NA]
A completed clinical trial evaluating cognitive bias modification as an adjunctive treatment for serious mental illness. Results have been p…
-
FDA approval · 2024-02-05FDA Approved: ESCITALOPRAM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for escitalopram from Macleods Pharmaceuticals Limited, authorizing changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2024-02-05Clinical Trial Update: Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients [Phase 3]
Phase 3 trial evaluating pharmacogenetic information using NEUROPHARMAGEN in the treatment of major depressive disorder has completed.
-
FDA approval · 2024-02-05FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Escitalopram Oxalate (escitalopram) by Exelan Pharmaceuticals Inc. under ANDA078604.
-
FDA approval · 2024-02-02FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for sertraline hydrochloride from Rising Pharma Holdings, Inc., resulting in approval of a gener…